Minerva Neurosciences (NASDAQ:NERV) PT Lowered to $7.00 at HC Wainwright

Minerva Neurosciences (NASDAQ:NERV) had its price target reduced by HC Wainwright from $11.00 to $7.00 in a report published on Thursday, Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Minerva Neurosciences’ Q1 2025 earnings at ($1.03) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.92) EPS.

Separately, StockNews.com downgraded Minerva Neurosciences from a hold rating to a sell rating in a report on Friday, February 23rd.

Minerva Neurosciences Trading Up 0.9 %

Shares of Minerva Neurosciences stock opened at $2.37 on Thursday. Minerva Neurosciences has a 12 month low of $2.29 and a 12 month high of $13.49. The firm has a market capitalization of $16.57 million, a P/E ratio of -0.53 and a beta of 0.27. The business has a fifty day simple moving average of $2.66 and a two-hundred day simple moving average of $5.30.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.07. Analysts predict that Minerva Neurosciences will post -1.89 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.